Essa Pharma Stock Today
| EPIX Stock | USD 1.79 0.02 1.10% |
Performance0 of 100
| Odds Of DistressLess than 45
|
ESSA Pharma is trading at 1.79 as of the 28th of November 2024; that is 1.1 percent decrease since the beginning of the trading day. The stock's open price was 1.81. ESSA Pharma has 45 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for ESSA Pharma are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of July 2015 | Category Healthcare | Classification Health Care |
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada. Essa Pharma is traded on NASDAQ Exchange in the United States.. The company has 44.39 M outstanding shares of which 1.15 M shares are currently shorted by private and institutional investors with about 0.36 trading days to cover. More on ESSA Pharma
Moving together with ESSA Stock
| 0.85 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against ESSA Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Fiscal Year End 10th of December 2024
ESSA Stock Highlights
| CEO and President and Director | David MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsESSA Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ESSA Pharma's financial leverage. It provides some insight into what part of ESSA Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
ESSA Pharma (EPIX) is traded on NASDAQ Exchange in USA. It is located in 999 West Broadway, Vancouver, BC, Canada, V5Z 1K5 and employs 50 people. ESSA Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 80.34 M. ESSA Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 44.39 M outstanding shares of which 1.15 M shares are currently shorted by private and institutional investors with about 0.36 trading days to cover.
ESSA Pharma currently holds about 174.6 M in cash with (19.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ESSA Pharma Probability Of Bankruptcy
Ownership AllocationESSA Pharma holds a total of 44.39 Million outstanding shares. The majority of ESSA Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in ESSA Pharma to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in ESSA Pharma. Please pay attention to any change in the institutional holdings of ESSA Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check ESSA Ownership Details
ESSA Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Parkman Healthcare Partners Llc | 2024-06-30 | 252.1 K | |
| Cibc World Markets Inc. | 2024-06-30 | 80.3 K | |
| D. E. Shaw & Co Lp | 2024-09-30 | 63 K | |
| American Century Companies Inc | 2024-09-30 | 46.7 K | |
| Bnp Paribas Arbitrage, Sa | 2024-06-30 | 43.6 K | |
| Kennedy Capital Management Inc | 2024-09-30 | 41.1 K | |
| Royal Bank Of Canada | 2024-06-30 | 36.3 K | |
| Citadel Advisors Llc | 2024-09-30 | 28.5 K | |
| Geode Capital Management, Llc | 2024-09-30 | 26.9 K | |
| Bvf Inc | 2024-09-30 | 8.7 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 8.4 M |
ESSA Pharma Historical Income Statement
ESSA Stock Against Markets
ESSA Pharma Corporate Management
| Erin Rudsinski | Executive | Profile | |
| CMA CPA | Chief Officer | Profile | |
| Terry Schuenemeyer | Executive | Profile | |
| Neil Thapar | Executive | Profile | |
| Nkengyal Barber | Executive | Profile | |
| Alessandra MD | Chief Officer | Profile |
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.